Disc Medicine financials
$65.87+1.46%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$65.1M | -$69.5M | -$67.0M | -$67.7M | -$61.4M | -$39.9M | -$34.5M | -$32.9M | -$30.9M | -$31.5M | -$29.7M | -$19.0M |
| Net income | -$59.5M | -$63.5M | -$60.5M | -$62.3M | -$55.2M | -$34.1M | -$29.5M | -$26.6M | -$26.4M | -$26.9M | -$23.6M | -$14.1M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-1.54 | $-1.65 | $-1.61 | $-1.77 | $-1.58 | $-1.02 | $-0.98 | $-0.89 | $-1.03 | $-1.09 | $-0.96 | $-0.58 |
| EBITDA | -$65.0M | -$69.4M | -$66.9M | -$67.6M | -$61.3M | -$39.9M | -$34.5M | -$32.8M | -$30.7M | -$31.4M | -$29.7M | -$18.9M |
| Operating cash flow | -$44.2M | -$62.2M | -$43.3M | -$47.8M | -$47.9M | -$41.4M | -$27.6M | -$17.4M | -$15.4M | -$33.6M | -$17.8M | -$7.5M |
| Free cash flow | -$44.2M | -$62.2M | -$43.3M | -$47.8M | -$48.0M | -$42.2M | -$28.0M | -$17.4M | -$15.4M | -$33.7M | -$17.8M | -$7.5M |
| Diluted shares | 38.7M | 38.5M | 37.7M | 35.2M | 35.0M | 33.3M | 30.0M | 29.9M | 25.6M | 24.8M | 24.5M | 24.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $98.7M | $88.9M | $91.1M | $140.7M | $127.3M | $122.7M |
| Short-term investments | $619.1M | $641.2M | $700.0M | $475.3M | $522.6M | $572.0M |
| Total debt | $59.3M | $29.4M | $29.2M | $28.9M | $28.7M | $28.5M |
| Total assets | $735.1M | $750.2M | $806.9M | $630.5M | $665.1M | $709.3M |
| Total liabilities | $90.9M | $61.8M | $67.1M | $57.1M | $50.9M | $48.9M |
| Shareholders' equity | $644.2M | $688.4M | $739.8M | $573.4M | $614.2M | $660.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology